Ashwagandha: dosage, extracts and safety questions

The data reviewed here do not point to any amount of ashwagandha that would be both effective and safe across all products. A dose used in a study is, first of all, a description of that particular trial. It does not become a personal recommendation just because guides keep repeating it.

What a milligram figure describes

With a herbal product, the first thing to establish is what the number refers to: plant powder, an extract or a declared constituent. According to the overview from the NIH Office of Dietary Supplements, the products studied differ in the plant parts used, the extraction method and their composition, among other things.

As a pure arithmetic example, 300 mg of an extract labeled as 5 percent withanolides works out to 15 mg of that declared group of compounds. The calculation proves neither a benefit nor a safe amount. It only shows why the mass of the extract and the constituent figure are different pieces of information. Even the same percentage does not automatically make two products clinically equivalent.

A higher concentration on its own therefore says nothing about a product’s quality. What would matter is whether that specific composition has been adequately studied for the intended goal. This often cannot be seen from the front of the package.

Do not treat study doses as building blocks

The amounts mentioned in the articles on stress, sleep and hormones belong to different protocols. The highest amount from several positive trials is therefore not automatically the “best dose.”

Nor can a study product be reproduced simply by converting the dose into a different number of capsules. That would require the relevant properties of the product to match. If this information is missing, it remains unclear whether the results carry over, and the gap should not be filled with a self-chosen dose.

What the BfR says about safety

The German Federal Institute for Risk Assessment (Bundesinstitut für Risikobewertung, BfR) was unable to derive a health-based guidance value for a safe intake from the available data. It specifically advises children, pregnant and breastfeeding women, and people with acute or existing liver disease to avoid ashwagandha products. It also urges caution for other population groups. BfR communication 39/2024.

This does not mean that every use is necessarily harmful, nor does it justify a blanket promise of safety. Even the lowest amount available in stores cannot stand in for a reliably established safe limit.

Medications and preexisting conditions

The NCCIH lists possible interactions with sedatives, thyroid hormones, immunosuppressants and medicines for diabetes, high blood pressure and seizures, among others. Use is not recommended for people with thyroid or autoimmune diseases or before surgery. Long-term data are not sufficient for a reliable safety assessment. NCCIH.

Whether an interaction is likely has to be checked against the actual products and doses. A catch-all term like “blood pressure medication” is not enough for that. Do not stop prescribed medicines on your own because of this list.

Liver problems are a relevant warning sign

A case series from Iceland and the US DILIN network (Drug-Induced Liver Injury Network) described five cases of liver injury attributed to ashwagandha products. Jaundice and other symptoms appeared after two to twelve weeks. Several of the people were taking additional supplements, and a case series cannot determine how common the risk is. Björnsson et al., primary report.

Yellowing of the skin or eyes while taking it should therefore not be dismissed as normal adjustment: stop the product and get medical advice promptly. The package and details of any other products you take are helpful for that assessment.

Morning, evening or in cycles?

The sources analyzed here do not establish a universally best time to take it. Nor can a fixed pattern of weeks on and weeks off be derived from them as a proven safety strategy. Schedules like these should not give the impression that they reliably eliminate known risks.

So the question of benefit comes before any question of amount: what specific problem is this meant to solve, and are there sufficiently relevant data for it? Only together with product details, preexisting conditions and medications can an individual decision be discussed with a professional.